Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes

Pfizer’s latest major pipeline clear-out resulted in losses of Sutent development in a number of cancers and figitumumab in non-small cell lung cancer, among many other discontinuations.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet